[e-drug] Humiragate (re Adalimumab)

e-drug
1

E-DRUG: Humiragate (re Adalimumab)
------------------------------------------------

Dear E-drug readers,

Here is my latest blog on how Abbvie is trying to maintain its market for Humira (ada.) in the Netherlands.

This piece is based on research published by investigative journalist Lucien Hordijk in the Groene Amsterdammer this week.

Humira is the brand name of the biologic medicine adalimumab and was first approved for the treatment of rheumatoid arthritis in the US in 2002 and in the EU in 2003. With close to 20 billion US$ in sales in 2018 Humira accounts for 70% of AbbVie’s total turnover. It is therefore no surprise that the company fiercely protects its market monopoly.

https://medicineslawandpolicy.org/2019/03/humiragate-abbvies-desperate-attempts-to-keep-its-monopoly/

Kind regards,

Ellen

Ellen ˜t Hoen LLM, PhD | Medicines Law & Policy
www.medicineslawandpolicy.org
E-mail: ellenthoen@medicineslawandpolicy.net